Clinical Trial Results:
A randomised, double-blind, placebo-controlled, ascending dose Phase I/IIa study to evaluate the safety, tolerability and efficacy of topical LTX-109 in subjects nasally colonized with methicillin-resistant/-sensitive Staphylococcus aureus (MRSA/MSSA).
Summary
|
|
EudraCT number |
2010-019254-40 |
Trial protocol |
SE |
Global completion date |
29 Apr 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Jul 2022
|
First version publication date |
09 Jul 2022
|
Other versions |
|
Summary report(s) |
LTX-109 is an Effective, Novel Agent for Nasal Decolonization of MRSA/MSSA – Results from a Phase I/IIa Study |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.